About AbbVie AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTubeand LinkedIn.
About Allergan Eye Care As a leader in eye care, Allergan has discovered, developed, and delivered some of the most innovative products in the industry for more than 70 years. Allergan has launched over 125 eye care products and invested billions of dollars in new treatments for the most prevalent eye conditions, including glaucoma, ocular surface disease, and retinal diseases such as diabetic macular edema and retinal vein occlusion.
At Bayer, we aim to reduce the impact of visual impairment on patients through innovation. We are committed to continuing research and development to address unmet needs, including identifying ways to minimize the treatment burden, increase treatment effectiveness and discover therapies for currently untreated eye diseases.
We offer EYLEA, a recognized treatment for various retinal diseases, such as neovascular(wet) AMD, DME and RVO. We are expanding expertise beyond exudative eye diseases through strategic alliances and collaborations, with established partners like Regeneron Pharmaceutics, the Wilmer Eye Institute and the DNDinitiative.
We have begun to expand into Cell & Gene Therapy cooperating with BlueRock Therapeutics, an independently operated wholly-owned Bayer subsidiary, and have established a strategic collaboration with Opsis Therapeutics and FUJIFILM Cellular Dynamics aiming to develop cell therapies for degenerative retinal conditions, focusing on inherited retinal disorders and dry AMD, for which there are no effective treatment options.
Novartis Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world. Find out more at
At Novartis, our mission is to discover new ways to improve and extend people’s lives. In ophthalmology, we develop and deliver life-changing medicines and therapies for diseases and conditions from front to back of the eye, enabled by data and transformative technologies. Our ophthalmic solutions reach more than 150M people per year, from premature infants to the elderly.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Chengdu Kanghong Pharmaceutical Group Co., Ltd. is dedicated to improving ophthalmic care through the development and commercialization of innovative products for a wide range of ocular conditions. Founded in 1996, the Group became a publicly listed company in China in 2015 and acquired IOPtima, a company in Israel dedicated to the development of ophthalmic devices.
About Conbercept Conbercept is a new generation anti-VEGF, a 100 percent humanized fusion protein that targets VEGF-B, placental growth factor, and various isoforms of VEGF-A. Conbercept has been approved and marketed in China as Lumitin®, for the treatment of retina diseases. In China, Conbercept was approved for the treatment of nAMD in 2014, for the treatment of pathological myopia associated with choroidal neovascularization (“pmCNV") in 2017, and for the treatment of diabetic macular edema (“DME") in 2019. A large number of real-world treatment and investigator-sponsored trials have shown conbercept to be safe and efficacious.
Horus Pharma is a French laboratory, founded in 2003.
Independent and family-owned company, we are focused on ophthalmology, acting in several countries across Europe. The Horus Pharma group is directly present in Spain, Belgium, the Netherlands, Luxembourg, and Switzerland. Our portfolio is also available in Italy, the UK, Germany, and Morocco, thanks to our key partners.
Our key strength is innovation related to a high-performing R&D policy.
We are covering all the therapeutic segments including glaucoma, retina, and cornea.
Acting both in pharmaceutical and surgical markets, we are a pioneer in the preservative-free culture. As a patient-oriented company, we strongly believe that the future relies not only on the strength of our innovative products, but also on the digitalization of our company, allowing us to bring service to the industry.
Patient-oriented, Horus Pharma is bringing broad, consistent, and innovative products and services to the European market.
Alimera Sciences is a pharmaceutical company that specialises in the commercialisation and development of prescription ophthalmic pharmaceuticals. It was founded in 2003 and is currently focused on diseases affecting the posterior segment of the eye. For more information, please visit www.alimerasciences.eu